Thymosin Alpha-1 10mg

Description

Thymosin Alpha-1 10mg

Thymosin alpha-1 (thymalfasin) is a 28-amino-acid peptide originally isolated from thymic tissue. Research interest centres on T-cell maturation and innate immune signalling, and it carries one of the largest clinical trial records of any compound in this catalogue.

Read the profile before you order. The published record does not support much of what is claimed for this compound. The largest sepsis trial — 1,106 patients, double-blind — found no survival benefit, and the hepatitis C figure most often quoted comes from a completers subgroup rather than the intention-to-treat analysis. Our compound profile sets out what has and has not been measured, including where the evidence is thin.

Certificate of analysis. This batch has not been received or tested yet. When a certificate exists it will be published at sentientbiogenix.com/coa/thymosin-a1-10mg and listed on our COA page.

*Sentient Biogenix products are intended solely for non‑clinical laboratory research. Thymosin alpha-1 is not an approved medicine in Canada or the United States. A thymalfasin product is authorised in Italy; this is not that product. It is not for human or animal consumption, nor for diagnostic, therapeutic, or clinical use.